E.V. Parshina, Alexey Zulkarnaev, A. Tolkach, Andrey Ivanov, P. Kislyy
{"title":"血液透析患者对 Gam-COVID-Vac 疫苗产生的长期体液和细胞反应:前瞻性队列研究","authors":"E.V. Parshina, Alexey Zulkarnaev, A. Tolkach, Andrey Ivanov, P. Kislyy","doi":"10.29333/ejgm/14786","DOIUrl":null,"url":null,"abstract":"Purpose: The aim of this study is to assess long-term immunogenicity of the recombinant adenoviruses 26 and 5 vector-based COVID-19 vaccine Gam-COVID-Vac (Sputnik V, developed by N. F. Gamaleya National Research Centre, Russia) in patients receiving maintenance hemodialysis (HD) compared to healthy subjects.\nMaterials & methods: A prospective cohort study included patients treated with maintenance HD (n=23) and healthy volunteers (n=28). The levels of anti-severe acute respiratory syndrome coronavirus-2 specific IgG as well as specific T-cell responses were quantified in all participants at two time points: one and six months after complete vaccination. All participates were adults, had been vaccinated twice with Gam-COVID-Vac and had no prior history of confirmed COVID-19.\nResults: In both groups, IgG levels decreased from month one to six, however, antibodies did not decline more rapidly in HD group (analysis of variance p=0.7214 for the “time×group” interaction, non-adjusted model). At the end of the study, 48.0% of non-HD and 67.0% of HD participants showed T-cell positivity. T-spot counts dropped over time in non-HD controls, but not in HD subjects (p=0.0080 and p=0.1800, respectively).\nConclusions: Patients receiving HD maintain significant long-term humoral response after Gam-COVID-Vac vaccination, which is comparable to that in subjects with normal kidney function. Cellular response turned up to be more sustained over time in HD group.","PeriodicalId":44930,"journal":{"name":"Electronic Journal of General Medicine","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term humoral and cellular responses elicited by Gam-COVID-Vac vaccine in hemodialysis patients: A prospective cohort study\",\"authors\":\"E.V. Parshina, Alexey Zulkarnaev, A. Tolkach, Andrey Ivanov, P. Kislyy\",\"doi\":\"10.29333/ejgm/14786\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: The aim of this study is to assess long-term immunogenicity of the recombinant adenoviruses 26 and 5 vector-based COVID-19 vaccine Gam-COVID-Vac (Sputnik V, developed by N. F. Gamaleya National Research Centre, Russia) in patients receiving maintenance hemodialysis (HD) compared to healthy subjects.\\nMaterials & methods: A prospective cohort study included patients treated with maintenance HD (n=23) and healthy volunteers (n=28). The levels of anti-severe acute respiratory syndrome coronavirus-2 specific IgG as well as specific T-cell responses were quantified in all participants at two time points: one and six months after complete vaccination. All participates were adults, had been vaccinated twice with Gam-COVID-Vac and had no prior history of confirmed COVID-19.\\nResults: In both groups, IgG levels decreased from month one to six, however, antibodies did not decline more rapidly in HD group (analysis of variance p=0.7214 for the “time×group” interaction, non-adjusted model). At the end of the study, 48.0% of non-HD and 67.0% of HD participants showed T-cell positivity. T-spot counts dropped over time in non-HD controls, but not in HD subjects (p=0.0080 and p=0.1800, respectively).\\nConclusions: Patients receiving HD maintain significant long-term humoral response after Gam-COVID-Vac vaccination, which is comparable to that in subjects with normal kidney function. Cellular response turned up to be more sustained over time in HD group.\",\"PeriodicalId\":44930,\"journal\":{\"name\":\"Electronic Journal of General Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Electronic Journal of General Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29333/ejgm/14786\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Electronic Journal of General Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29333/ejgm/14786","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究旨在评估基于重组腺病毒 26 和 5 载体的 COVID-19 疫苗 Gam-COVID-Vac (Sputnik V,由俄罗斯 N. F. Gamaleya 国家研究中心开发)在接受维持性血液透析(HD)的患者中与健康受试者相比的长期免疫原性:前瞻性队列研究包括接受维持性血液透析治疗的患者(23 人)和健康志愿者(28 人)。所有参与者的抗严重急性呼吸系统综合征冠状病毒-2 特异性 IgG 和特异性 T 细胞反应水平在两个时间点进行了量化:完全接种疫苗后的 1 个月和 6 个月。所有参与者均为成年人,接种过两次 Gam-COVID-Vac 疫苗,且之前没有确诊过 COVID-19 的病史:结果:两组的 IgG 水平从第 1 个月到第 6 个月都有所下降,但 HD 组的抗体下降速度并没有更快("时间×组 "交互作用的方差分析 p=0.7214,非调整模型)。研究结束时,48.0% 的非 HD 参与者和 67.0% 的 HD 参与者显示出 T 细胞阳性。随着时间的推移,非 HD 对照组的 T 点计数下降,但 HD 受试者的 T 点计数没有下降(分别为 p=0.0080 和 p=0.1800):结论:接种 Gam-COVID-Vac 疫苗后,接受 HD 治疗的患者长期保持明显的体液反应,与肾功能正常的受试者相当。血液透析组的细胞反应更持久。
Long-term humoral and cellular responses elicited by Gam-COVID-Vac vaccine in hemodialysis patients: A prospective cohort study
Purpose: The aim of this study is to assess long-term immunogenicity of the recombinant adenoviruses 26 and 5 vector-based COVID-19 vaccine Gam-COVID-Vac (Sputnik V, developed by N. F. Gamaleya National Research Centre, Russia) in patients receiving maintenance hemodialysis (HD) compared to healthy subjects.
Materials & methods: A prospective cohort study included patients treated with maintenance HD (n=23) and healthy volunteers (n=28). The levels of anti-severe acute respiratory syndrome coronavirus-2 specific IgG as well as specific T-cell responses were quantified in all participants at two time points: one and six months after complete vaccination. All participates were adults, had been vaccinated twice with Gam-COVID-Vac and had no prior history of confirmed COVID-19.
Results: In both groups, IgG levels decreased from month one to six, however, antibodies did not decline more rapidly in HD group (analysis of variance p=0.7214 for the “time×group” interaction, non-adjusted model). At the end of the study, 48.0% of non-HD and 67.0% of HD participants showed T-cell positivity. T-spot counts dropped over time in non-HD controls, but not in HD subjects (p=0.0080 and p=0.1800, respectively).
Conclusions: Patients receiving HD maintain significant long-term humoral response after Gam-COVID-Vac vaccination, which is comparable to that in subjects with normal kidney function. Cellular response turned up to be more sustained over time in HD group.